Feb 18, 2026Rapamycin in Older Adults: PEARL Trial Findings on Dose, Sex Differences, and Body CompositionThe PEARL trial tested low-dose weekly rapamycin in healthy older adults. The primary endpoint — visceral fat reduction — was not met. Secondary analyses suggested lean tissue effects at higher doses in women, but these require confirmation in adequately powered trials.
Feb 18, 2026POLYCAD Trial: Spermidine Supplementation in Coronary Artery Disease — Design and Interim ContextThe POLYCAD trial is testing 24 mg/day spermidine in 187 older adults with coronary artery disease for 48 weeks. Trial completion is expected August 2026 — no efficacy results exist yet. Prior cohort data from Eisenberg et al. 2016 provides the rationale.